Reciprocal blocking studies performed with 5 anti-GPIIb monoclonals*
| Blocking antibody . | Detecting antibody (biotin-labeled) . | ||||
|---|---|---|---|---|---|
| 314.1 . | 314.3 . | 10E5 . | 312.6 . | 312.8 . | |
| 314.1 | 100 | 99.4 | 84.8 | 98.7 | 0.5 |
| 314.3 | 98.7 | 100 | 70.3 | 96.5 | 0.0 |
| 10E5 | 99.0 | 100 | 100 | 40.5 | 43.4 |
| 312.6 | 99.7 | 99.8 | 0.0 | 100 | 15.6 |
| 312.8 | 4.4 | 3.1 | 41.8 | 5.3 | 100 |
| Blocking antibody . | Detecting antibody (biotin-labeled) . | ||||
|---|---|---|---|---|---|
| 314.1 . | 314.3 . | 10E5 . | 312.6 . | 312.8 . | |
| 314.1 | 100 | 99.4 | 84.8 | 98.7 | 0.5 |
| 314.3 | 98.7 | 100 | 70.3 | 96.5 | 0.0 |
| 10E5 | 99.0 | 100 | 100 | 40.5 | 43.4 |
| 312.6 | 99.7 | 99.8 | 0.0 | 100 | 15.6 |
| 312.8 | 4.4 | 3.1 | 41.8 | 5.3 | 100 |
Values shown indicate the extent to which preincubation with unlabeled antibody (3 μg; first column) blocked the binding of biotin-labeled (detecting) antibody (0.5 μg) to platelets expressed as a percentage of the signal obtained with detecting antibody alone (average of triplicate determinations). A value of 100 indicates complete blocking.